Sanofi Loses Bid to Revive Lantus Solostar Insulin-Pen Patents
- Viatris invalidates five Sanofi patents on injection pens
- Sanofi has been accused of using patents to thwart competition
This article is for subscribers only.
Sanofi lost its appeals court bid to revive patents on its blockbuster Lantus SoloStar insulin injection pen in a victory for drugmaker Viatris Inc.
A review board was correct to invalidate five patents for a pen-type injection device that allows a user to set and administer a dose of medication, the U.S. Court of Appeals for the Federal Circuit said in a series of three rulings Wednesday.